BioSpace News Archive

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & CEO, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 3:00PM ET, in New York City.

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that it has not yet received a decision from the U.S. Food and Drug Administration (FDA) on its 505(b)(2) New Drug Application (NDA) for ACER-001.

Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.

June 7, 2022 11:05 UTC In Vivo Preclinical Data Expected to Enable Three New IND Applications to Evaluate Company’s Gamma Delta T cell Product Candidates Procel™, Isocel™, and Deltacel™.

Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.

Freenome, a privately held biotech company, presented findings at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that demonstrate the clinical utility of detecting not just colorectal cancer (CRC), but also precancerous adenomas in a Medicare-aged cohort for tests that screen for CRC and multi-cancer early detection (MCED) tests that include CRC.

Freespira, Inc., maker of the first FDA-cleared digital therapeutic treatment for panic attacks, panic disorder and post-traumatic stress disorder, announced the appointment of Joseph Perekupka as Chief Executive Officer.

With compelling competition for its research grant, the PMD Foundation is pleased to announce the unprecedented funding of two research projects totaling $200,000.